Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine. Following a recent review, warnings for IIH are being added to the product information for all mesalazine products.
Similar Posts
Falsified Mounjaro KwikPen 15mg pre-filled pens
A falsified version of Mounjaro (tirzepatide) KwikPen 15mg solution for injection has been found supplied through one online pharmacy in the UK. The falsified product is labelled with batch D873576 and applies to Mounjaro KwikPen 15mg solution for injection in pre-filled pen only.
Class 4 Medicines Defect Notification: Olmesartan medoxomil 10mg film-coated tablets, Jubilant Pharmaceuticals NV, EL(25)A/37
Jubilant Pharmaceuticals NV has informed the MHRA that the Patient Information leaflet (PIL) in the cartons for the batches listed in this notification include an outdated PIL.
MHRA and NICE invite early adopters to trial accelerated aligned pathway – six months ahead of schedule
Aligned pathway will streamline decisions on licensing and value for medicines, helping patients to benefit from them sooner.
Patient and family experiences inform antidepressant safety information review
An Expert Working Group has completed a review into how the potential risks associated with antidepressant medicines are communicated to patients
Guidance: The Innovative Devices Access Pathway (IDAP)
The Innovative Devices Access Pathway (IDAP) pilot is designed to accelerate the development of innovative medical devices that meet an unmet clinical need in the NHS and support their integration into the UK market.
MHRA welcomes Professor Jacob George as he starts Chief Medical and Scientific Officer role
In this new role, Professor George will lead the Agency’s science strategy and will oversee the MHRA’s scientific, research and innovation activities.